Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track GANX with free AI briefings, catalyst countdowns, and dilution alerts.

GANX · Gain Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$11.7M Cash on Hand
9.1mo Cash Runway
Follow GANX by email Get an email when GANX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about GANX, unsubscribe in one click. Privacy

📣 What GANX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
High Dose GT-02287 Parkinson Disease Phase 2 · NCT07280299 Not yet recruiting
Low Dose GT-02287 Parkinson Disease Phase 2 · NCT07280299 Not yet recruiting
GT-02287 Parkinson Disease Phase 1 · NCT06732180 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

GANX holds $11.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $3.9M/quarter from operations, an estimated runway of 9.1 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 77 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GANX files for a raise →

👥 Who Owns GANX

Insiders 2.9% Institutions (59 holders) 18.8% Public and other holders 78.3%
HolderTypeShares% of sharesAs of
Khalid Islam
Director · +55,000 options
Insider 930,784 2.09% 2024-08-09
Eric I Richman
Director · +30,000 options
Insider 304,458 0.68% 2024-07-01
Jeffrey Scott Riley
Director · +55,000 options
Insider 30,000 0.07% 2024-03-28
Matthias Alder
Chief Executive Officer, Director · +376,376 options
Insider 21,140 0.05% 2024-03-26
Gene Mack
CEO, President, Director · +871,325 options
Insider 14,400 0.03% 2024-08-09

Share count 44,525,347 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full GANX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GANX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.